Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated

How Long Does EGPA Diagnosis Take After Asthma Starts?

At a Glance

EGPA is often diagnosed 10 to 12 years after asthma symptoms begin, although the delay can range from a few years to more than 30. New nerve, skin, kidney, digestive, or breathing symptoms and high eosinophil levels should prompt medical evaluation.

In studies of adults with EGPA, the average time from the start of asthma symptoms to an EGPA diagnosis is roughly 10 to 12 years [1][2]. However, this is just an average—research shows timelines ranging from a few years to over 30 years depending on the patient [2]. If you feel frustrated that you struggled with severe asthma for years before doctors figured out what was really going on, your experience is incredibly common and valid.

It usually takes the appearance of systemic (body-wide) symptoms—like nerve pain, unusual rashes, or organ issues—for specialists to realize your asthma is part of a broader, rare condition rather than occurring on its own [3][4].

The Three-Phase Model of EGPA

A major reason for this delay is that EGPA (Eosinophilic Granulomatosis with Polyangiitis) is an evolving disease. Doctors often describe it as unfolding in three phases [5]. Note: This is a conceptual model, not a strict timeline. The phases often overlap, can happen out of order, and organ inflammation can occur even without obvious vasculitis.

  1. The Prodromal (Allergic) Phase: For years, the only signs of the disease might be severe adult-onset asthma, chronic sinus inflammation (rhinosinusitis), and nasal polyps (painless, noncancerous growths in the nose) [5][6]. Because millions of people have asthma and allergies, it can be difficult for doctors to distinguish early EGPA from common asthma [7].
  2. The Eosinophilic Phase: The body overproduces eosinophils (a type of white blood cell involved in allergic reactions) [8]. These cells build up in the blood and can start infiltrating tissues, particularly the lungs and digestive tract.
  3. The Vasculitic Phase: In this stage, actual vasculitis (inflammation of the blood vessels) occurs [9]. The inflamed vessels restrict blood flow to various organs, causing severe symptoms like nerve damage, skin rashes, or kidney problems [9][10].

Factors That Delay Diagnosis

Several factors create a “diagnostic odyssey” for patients:

  • Symptom Overlap: Because severe asthma dominates the early years of the disease, new symptoms that slowly appear are often mistakenly blamed on the asthma or its complications [11]. Most people with asthma do not have EGPA, making this rare disease hard to spot.
  • Medications Can Mask Symptoms: The treatment for severe asthma often involves systemic corticosteroids (oral steroids like prednisone) [12]. While inhaled steroids act locally, oral steroids work systemically to suppress eosinophil levels and reduce inflammation. As a result, the oral steroids treating your asthma flares may have temporarily masked the broader symptoms of EGPA for years [11].
    • Important Safety Warning: Never stop or reduce your prescribed asthma medications or oral steroids without explicit guidance from your doctor.
  • The ANCA Test Is Not Always Positive: Doctors often use a blood test looking for ANCA (antineutrophil cytoplasmic antibodies, which are autoantibodies directed against specific proteins in certain white blood cells) to evaluate for vasculitis [13]. However, only about 30% to 35% of EGPA patients test positive for ANCA [13]. A negative result does not rule out EGPA, but it can sometimes give doctors a false sense of security [14].

Red Flags: When to Seek Medical Attention

The turning point in an EGPA diagnosis usually happens when asthma is accompanied by “red flag” symptoms. It is crucial to know which symptoms require immediate emergency care and which should prompt an evaluation with your specialist.

Seek Immediate / Emergency Care for:

  • Sudden, severe chest pain or fainting [3]
  • Sudden focal weakness, such as foot drop (inability to lift the front part of the foot) or stroke-like symptoms [4]
  • Severe shortness of breath not relieved by your usual asthma rescue inhalers
  • Severe abdominal pain or gastrointestinal bleeding [15]

Prompt a Medical Evaluation for:

  • Persistently high eosinophil levels on routine blood tests [3]
  • Mononeuritis multiplex (nerve damage causing pain, tingling, or numbness, often in an asymmetrical pattern like one foot or one wrist) [4]
  • Purpura (purple or red spots on the skin caused by bleeding underneath) [4]
  • Unexplained changes in kidney function or urine tests [10]

Common questions in this guide

How long does it usually take to diagnose EGPA after asthma starts?
In studies of adults with EGPA, the average interval from the start of asthma symptoms to diagnosis is about 10 to 12 years. Individual timelines vary widely, from a few years to more than 30 years, so this average cannot predict one person’s experience.
Why can EGPA look like ordinary asthma for so long?
Early EGPA may cause severe adult-onset asthma, sinus inflammation, and nasal polyps, which are also common conditions. Later nerve, skin, digestive, kidney, or other organ symptoms may reveal that inflammation is affecting the whole body, while oral steroids can temporarily reduce signs of disease.
Does a negative ANCA blood test rule out EGPA?
No. Only about 30% to 35% of people with EGPA have a positive ANCA result, so a negative test does not exclude the condition. Doctors interpret ANCA alongside symptoms, eosinophil levels, and evidence of organ involvement.
Which symptoms require emergency care when EGPA is possible?
Seek emergency care for sudden severe chest pain or fainting, new focal weakness such as foot drop or stroke-like symptoms, severe shortness of breath that does not improve with your usual rescue inhaler, or severe abdominal pain or gastrointestinal bleeding. Do not wait for a routine appointment when these symptoms occur.
Can asthma medicines hide signs of EGPA?
Yes. Oral or other systemic corticosteroids can lower eosinophil levels and suppress inflammation, temporarily masking symptoms outside the lungs. Never stop or reduce prescribed steroids or other asthma medicines without explicit guidance from your clinician.
What should doctors check if someone with asthma may have EGPA?
Evaluation may include reviewing eosinophil counts over time, considering an ANCA blood test, and checking for silent organ involvement, including effects on the heart or kidneys. Your clinician should interpret these findings in light of your symptoms and current steroids or biologic medicines.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my history of asthma and now EGPA, are there any organs (like my heart or kidneys) that we need to screen for silent involvement?
  2. 2.Should I be tested for ANCA antibodies, and how does that result change my monitoring or treatment plan?
  3. 3.How do my current asthma medications—especially any systemic steroids or biologics—affect how we interpret my eosinophil counts?
  4. 4.What specific 'red flag' symptoms should I watch for that require immediate emergency care versus a routine call to the clinic?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

    Cottin V, Bel E, Bottero P, et al.

    The European respiratory journal 2016; (48(5)):1429-1441 doi:10.1183/13993003.00097-2016.

    PMID: 27587545
  2. 2

    Characteristics of Severe Asthma Clinic Patients With Eosinophilic Granulomatosis With Polyangiitis.

    Puan Y, Ong KY, Tiew PY, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(2)):361-368.e2 doi:10.1016/j.jaip.2024.10.013.

    PMID: 39424190
  3. 3

    [Cardiac involvement in Churg-Strauss syndrome].

    Brucato A, Maestroni S, Masciocco G, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

    PMID: 26418389
  4. 4

    Asthma-free eosinophilic granulomatosis with polyangiitis presenting with Guillain-Barré syndrome-like symptoms: a case report.

    Huang H, Zhao X, Zhou Y, et al.

    Frontiers in medicine 2026; (13()):1837875 doi:10.3389/fmed.2026.1837875.

    PMID: 42328565
  5. 5

    Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients.

    Choi CB, Park YB, Lee SW

    Yonsei medical journal 2019; (60(8)):705-712 doi:10.3349/ymj.2019.60.8.705.

    PMID: 31347324
  6. 6

    Early Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Poliangioitis: Results from Our Cohort Group and Literature Review.

    D'Onofrio M, La Prova D, Galdiero MR, et al.

    Journal of clinical medicine 2023; (12(22)) doi:10.3390/jcm12226967.

    PMID: 38002582
  7. 7

    A delayed diagnosis of eosinophilic granulomatosis with polyangiitis complicated with extensive artery occlusion of lower extremities in children: case report and literature review.

    Liu X, Wang L, Zhou K, et al.

    Pediatric rheumatology online journal 2019; (17(1)):26 doi:10.1186/s12969-019-0331-8.

    PMID: 31138304
  8. 8

    Eosinophilic granulomatosis with polyangiitis presenting with myositis: case based review.

    Koppikar S, Al-Dabie G, Jerome D, Vinik O

    Rheumatology international 2020; (40(7)):1163-1170 doi:10.1007/s00296-020-04567-8.

    PMID: 32270295
  9. 9

    [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].

    Hellmich B, Holle J, Moosig F

    Zeitschrift fur Rheumatologie 2022; (81(4)):286-299 doi:10.1007/s00393-021-01153-6.

    PMID: 35075511
  10. 10

    Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement.

    Afiari A, Gabriel A, Gaiki MR

    Cureus 2020; (12(7)):e9242 doi:10.7759/cureus.9242.

    PMID: 32821588
  11. 11

    Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review.

    Wu EY, Hernandez ML, Jennette JC, Falk RJ

    The journal of allergy and clinical immunology. In practice 2018; (6(5)):1496-1504 doi:10.1016/j.jaip.2018.07.001.

    PMID: 30197069
  12. 12

    Prevasculitic Eosinophilic Granulomatosis With Polyangiitis.

    Burtson KM, Bishop J

    Cureus 2021; (13(4)):e14649 doi:10.7759/cureus.14649.

    PMID: 34055509
  13. 13

    International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.

    Moiseev S, Bossuyt X, Arimura Y, et al.

    American journal of respiratory and critical care medicine 2020; (202(10)):1360-1372 doi:10.1164/rccm.202005-1628SO.

    PMID: 32584187
  14. 14

    Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis.

    Chang HC, Chou PC, Lai CY, Tsai HH

    The journal of allergy and clinical immunology. In practice 2021; (9(1)):445-452.e6 doi:10.1016/j.jaip.2020.07.038.

    PMID: 32771687
  15. 15

    Multiple ulcerations and perforation in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review.

    Ito Y, Yoshida M, Sugiyama T, et al.

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2020; (47()):107193 doi:10.1016/j.carpath.2019.107193.

    PMID: 32151788

This page is for informational purposes only and does not constitute medical advice. It explains diagnostic delays in EGPA, but do not stop or change asthma medicines or steroids without guidance from your clinician.

Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.